Viking Therapeutics, Inc. stock: filings, catalysts and timeline
Sign in to follow
FundamentalsWhat is this?HideToo few of the required measures on file
How the business is doing on its own reported US-GAAP numbers — growth, margins, cash generation, balance-sheet strength, capital efficiency and dilution — compared with sector peers.
Source: SEC XBRL financial statements.
ValueWhat is this?HidePre-revenue — no valuation basis
How the shares are priced against sector peers, against the company's own recent history, and against a simple cash-flow estimate, using the filing numbers and the current price. AIR shows this as a band, never as a target price.
Source: SEC XBRL financial statements and end-of-day prices.
News flowWhat is this?HideBalanced
What the company has documented recently: material 8-K events (contracts, deals, results, leadership changes) and FDA approvals, weighted by recency and type. A language model's reading of each 8-K helps classify whether it is positive or negative. Filings, not press or social media.
Source: SEC EDGAR 8-K filings and FDA approvals.
MomentumWhat is this?HideWeak
The longer-term market read: the trend in end-of-day prices, strength against the market and the sector, and trading volume over roughly the past three to twelve months. It is shown, never used to rank the Shortlist.
Source: End-of-day prices.
SafetyWhat is this?HideStrong
The risk side: leverage, liquidity, cash runway, dilution, revenue and margin swings, company size and pre-commercial status, negative 8-K events (including legal and regulatory ones), and share-price drawdown and volatility. Higher means fewer of those risk markers.
Source: SEC XBRL financial statements, SEC EDGAR 8-K filings and end-of-day prices.
Fundamental score not available. AIR's fundamental engine is built for businesses with established revenue and cash flow; biotech financial profiles — often R&D-heavy or pre-revenue — don't yet fit the measures it requires. AIR still assesses this company on News flow, Momentum and Safety, and the missing score lowers its Evidence strength.
Discovery Gap: High (33/100) · Gap confidence 57/100
Filings show more traction than the tape reflects.
Low is the most common level — the cut-offs are fixed, and levels can shift as scores refresh.
What is this?Hide
How far documented progress (News flow) runs ahead of market attention. Attention is measured from institutional holdings reported to the SEC, trading volume, price behaviour and how richly the shares are valued — not from social media or analyst ratings.
Source: SEC EDGAR filings (8-K and 13F), FDA approvals and end-of-day prices.
How levels work. The levels use fixed cut-offs, but market attention is ranked against the other ~1,800 companies AIR covers that day (valuation against the same sector). Documented progress counts filings from the past 18 months, newer ones weighing more; attention uses the latest quarter of institutional holdings, the last three to six months of trading, and six to twelve months of price behaviour. Many companies show a Low Gap or none at all — a gap needs filings that read more positively than neutral. A level can change from one day to the next as scores refresh and the other companies move.
Gap confidenceWhat is this?HideModerate 57/100How fully AIR could measure this Gap.
How fully AIR could measure both sides of the Discovery Gap: the documented progress (News flow) and market attention (Recognition). It takes the weaker of the two, and reads zero when either side has no measurement. It describes the data, not the company.
Evidence strengthWhat is this?HideModerate 36/100Support behind the full AIR read, not only the Gap.
How much data stands behind the whole AIR read — all five perspectives, not just the Discovery Gap. Each perspective reports how complete its inputs are, and these are combined in the same proportions as the AIR Score; a perspective AIR could not score adds nothing, so missing data lowers this figure. It describes the data, not the company.
This month at a glance
Evidence timeline
- Expected
Thu 11 Feb · expected 10-K
Last year filed 11 Feb 2026.
Fri 30 Apr · expected 10-Q
Last year filed 30 Apr 2026.
- Filed
Thu 29 Oct · 10-Q
Wed 28 Oct · 8-K
8-K · Item 2.02 — Results of operations
Viking reports Q3 2026 results with multiple positive clinical milestones: VANQUISH Phase 3 trials advancing on track, SUNRISE oral Phase 3 program initiated, positive maintenance dosing results for VK2735, VK3019 Phase 1 nearing completion, and $960M cash position secured via capital raise.
Recognition: Strong 72 → Strong 76More of the market is starting to notice.
The price trend strengthened.
Mon 28 Sep · 8-K
8-K · Items 1.01, 2.03 — Material agreement
Viking Therapeutics completed concurrent equity and convertible debt offerings, raising ~$297M net (equity) and ~$251M net (debt) for total ~$548M. Proceeds designated for VK2735 and VK3019 clinical development and commercialization.
Tue 22 Sep · 8-K
8-K · Item 8.01 — Other events
Recognition: Strong 66 → Very strong 81More of the market is starting to notice.
The price trend strengthened.
Wed 29 Jul · 10-Q
Quarterly report (10-Q), period ending 15 Jul 2026
Wed 29 Jul · 8-K
Tue 26 May · 8-K
Thu 30 Apr · 10-Q
Quarterly report (10-Q), period ending 15 Apr 2026
Wed 29 Apr · 8-K
Wed 11 Feb · 8-K
Wed 11 Feb · 10-K
Annual report (10-K), FY2026
Thu 23 Oct · 10-Q
Quarterly report (10-Q), period ending 15 Oct 2025
Wed 22 Oct · 8-K
Solid dots: a filing AIR classified as material. Grey: routine. Hollow: expected, from last year's dates — not a forecast.
Ask AIR
What would change our view
Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.